This in vitro model, with its varied cell composition and biomimetic structure, serves as a valuable resource for liver disease research, drug development, and regenerative medicine studies.

Blocking a key metabolic enzyme helps B cells fight liver tumors, revealing a new immunotherapy pathway for fatty liver–driven cancer in mice.

Eureka Therapeutics, Inc., a clinical-stage biotechnology company pioneering safer and more effective T-cell therapies, today announced the appointment of Samuel So, MBBS, FACS, a globally recognized ...

Stem cell research and therapy for liver and kidney diseases is a rapidly evolving field with significant therapeutic ...

Over 80% of hepatocellular carcinoma (HCC) – the third-leading cause of cancer deaths globally – emerges from advanced liver fibrosis or cirrhosis. A comprehensive review in Hepatology International ...

Moreover, our findings may explain why, although renal cells begin to express EPO at birth, the decrease in expression of a more-active liver EPO leads to a decrease in the red-cell count in ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced end-of-treatment data from Part B of the MARCH Phase 2 clinical study evaluating combinations of ...